These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Synthesis of Rapamycin Derivatives Containing the Triazole Moiety Used as Potential mTOR-Targeted Anticancer Agents. Xie L; Huang J; Chen X; Yu H; Li K; Yang D; Chen X; Ying J; Pan F; Lv Y; Cheng Y Arch Pharm (Weinheim); 2016 Jun; 349(6):428-41. PubMed ID: 27150260 [TBL] [Abstract][Full Text] [Related]
3. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells. Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR. Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223 [TBL] [Abstract][Full Text] [Related]
6. Benzofuran derivatives as anticancer inhibitors of mTOR signaling. Salomé C; Ribeiro N; Chavagnan T; Thuaud F; Serova M; de Gramont A; Faivre S; Raymond E; Désaubry L Eur J Med Chem; 2014 Jun; 81():181-91. PubMed ID: 24836070 [TBL] [Abstract][Full Text] [Related]
7. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415. Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631 [TBL] [Abstract][Full Text] [Related]
8. Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115. Mortensen DS; Perrin-Ninkovic SM; Shevlin G; Elsner J; Zhao J; Whitefield B; Tehrani L; Sapienza J; Riggs JR; Parnes JS; Papa P; Packard G; Lee BG; Harris R; Correa M; Bahmanyar S; Richardson SJ; Peng SX; Leisten J; Khambatta G; Hickman M; Gamez JC; Bisonette RR; Apuy J; Cathers BE; Canan SS; Moghaddam MF; Raymon HK; Worland P; Narla RK; Fultz KE; Sankar S J Med Chem; 2015 Jul; 58(14):5599-608. PubMed ID: 26102506 [TBL] [Abstract][Full Text] [Related]
10. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin. Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032 [TBL] [Abstract][Full Text] [Related]
11. Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1. Wang YD; Su YJ; Li JY; Yao XC; Liang GJ Int J Clin Exp Pathol; 2015; 8(5):5182-8. PubMed ID: 26191215 [TBL] [Abstract][Full Text] [Related]
12. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway. Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition. Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132 [TBL] [Abstract][Full Text] [Related]
14. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition. Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582 [TBL] [Abstract][Full Text] [Related]
15. 1,2,4-Triazolin-5-thione derivatives with anticancer activity as CK1γ kinase inhibitors. Pitucha M; Janeczko M; Klimek K; Fornal E; Wos M; Pachuta-Stec A; Ginalska G; Kaczor AA Bioorg Chem; 2020 Jun; 99():103806. PubMed ID: 32279038 [TBL] [Abstract][Full Text] [Related]
16. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225 [TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis and Biological Evaluation of Novel Rapamycin Benzothiazole Hybrids as mTOR Targeted Anti-cancer Agents. Xie L; Huang J; Chen X; Yu H; Li K; Yang D; Chen X; Ying J; Pan F; Lv Y; Cheng Y Chem Pharm Bull (Tokyo); 2016; 64(4):346-55. PubMed ID: 26842804 [TBL] [Abstract][Full Text] [Related]
18. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents. Peng W; Tu ZC; Long ZJ; Liu Q; Lu G Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167 [TBL] [Abstract][Full Text] [Related]
19. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses. Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759 [TBL] [Abstract][Full Text] [Related]
20. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways. Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]